Cellectis shares soar 15% ahead of third-quarter results
The Paris-based biotech posts one of the strongest rebounds of the session, one day before its financial release. The move extends a recovery that began last week, following a very difficult quarter.
A rebound that reclaims the MA20 but remains far from long-term averages
The stock trades at €1.21 and gains 15.06% during the session, after closing the previous day at €1.05. It also gains nearly 17% over the week, which erases only part of the 50.9% decline suffered over three months.
The price has clearly moved back above the MA20 (€1.02, a gap of +18.3%), but remains below the MA50 (€1.37) and well below the MA200 (€2.58).
Resistance at €1.34 is the next identified level, while support stands at €0.94. The stock had recovered at the end of October, after a rebound of nearly 16% on preclinical data presented in Germany (the October 28 rebound).
Third-quarter results expected tomorrow, following data on APOC3
Cellectis will publish its third-quarter 2026 results on November 12. The release follows the presentation, at the end of October at the ESGCT congress in Hamburg, of data on its in vivo base editing candidate targeting the APOC3 gene: a single administration had reduced triglycerides by 75% on average in mice, and the group plans a phase 1 trial in China (the preclinical triglyceride data).
On the trading side, Cellectis is also listed on Nasdaq via its ADSs (CLLS), at a ratio of one ADS per ordinary share. On the Paris market, the CAC 40 gains 0.26% and the SBF 120 gains 0.28%, while the biotech is rising more than fifty times faster than the latter.
